thalidomide has been researched along with Extranodal NK-T-Cell Lymphoma in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wen, H | 1 |
| Ma, H | 1 |
| Cai, Q | 1 |
| Lin, S | 1 |
| Lei, X | 1 |
| He, B | 1 |
| Wu, S | 1 |
| Wang, Z | 1 |
| Gao, Y | 1 |
| Liu, W | 2 |
| Tao, Q | 1 |
| Long, Z | 1 |
| Yan, M | 1 |
| Li, D | 1 |
| Kelley, KW | 1 |
| Yang, Y | 1 |
| Huang, H | 1 |
| Liu, Q | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273529] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-02-20 | Not yet recruiting | ||
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273581] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-02-18 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for thalidomide and Extranodal NK-T-Cell Lymphoma
| Article | Year |
|---|---|
Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Calgranulin A; Calgranulin B; Dexamethasone; Exome Sequ | 2018 |
Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Calgranulin A; Calgranulin B; Dexamethasone; Exome Sequ | 2018 |
Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Calgranulin A; Calgranulin B; Dexamethasone; Exome Sequ | 2018 |
Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Calgranulin A; Calgranulin B; Dexamethasone; Exome Sequ | 2018 |